NLRP3 and type 2 diabetes mellitus: The monoclonal antibody of IL-1β, canakinumab, could suppress NLRP3 inflammasome signaling and significantly reduce systemic inflammation in type 2 diabetes patients infected with SARS-CoV-2 [17].